Michelle Shuffett
RS BioTherapeutics Appoints Michelle L. Shuffett, MD as SVP of Medical and Scientific Affairs
05 juin 2023 07h00 HE | RS BioTherapeutics
CUMBERLAND, Md., June 05, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life...
logo-blue-large.png
VaxEquity and CPI Announces Innovate UK Grant to Accelerate Next Generation RNA Vaccines and Therapeutics
05 juin 2023 03h00 HE | VaxEquity
CAMBRIDGE, United Kingdom, June 05, 2023 (GLOBE NEWSWIRE) -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform, and...
Culture Biosciences Logo (no background).png
Culture Biosciences Establishes Advisory Board of Biotech and Biopharma Executives to Guide the Corporate Strategy and Accelerate Growth
01 juin 2023 08h31 HE | Culture Biosciences
SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences today announced the formation of its inaugural Advisory Board. The group of seasoned biotech and biopharma executives will...
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering
26 mai 2023 16h05 HE | Biodexa Pharmaceuticals PLC
26 May 2023 Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering               Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a...
Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering
24 mai 2023 08h40 HE | Biodexa Pharmaceuticals PLC
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH...
Posting of Annual Report & Notice of AGM
22 mai 2023 16h15 HE | Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company...
Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
18 mai 2023 08h30 HE | Biodexa Pharmaceuticals PLC
18 May 2023 Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the...
RS BioTherapeutics Logo.jpg
RS BioTherapeutics Joins BioNTX Bioscience and Healthcare Innovation Trade Organization
15 mai 2023 10h00 HE | RS BioTherapeutics
CUMBERLAND, Md., May 15, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life...
SiSaf-Logo-1200-x-630-85.jpg
FDA Grants SiSaf’s Innovative siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation for the Treatment of Autosomal Dominant Osteopetrosis
15 mai 2023 03h00 HE | SiSaf Ltd
GUILDFORD, England, May 15, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA delivery and therapeutics company, announces that SIS-101-ADO, its siRNA therapeutic for patients with Autosomal Dominant...
Disease Modeling and Target Identification Course from Insilico Medicine
UAE Biotech Insilico Medicine Offers Disease Modeling and Target Identification Course Using AI
12 mai 2023 08h40 HE | InSilico Medicine
Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced that it is releasing a course on Disease Modeling...